Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Innate and myeloid checkpoint antibodies act on macrophages, natural killer (NK) cells and other innate immune cells. Magrolimab blocks CD47, which binds signal-regulatory protein alpha (SIRPĪ±) on macrophages and suppresses phagocytosis of target cells. Monalizumab targets the inhibitory NK cell receptor NKG2A, which recognizes HLA-E on tumor cells. Axatilimab and cabiralizumab bind colony-stimulating factor 1 receptor (CSF1R) and are used to study tumor-associated macrophages in vitro and in vivo. Further antibodies target sialic acid-binding Ig-like lectins (Siglecs), TREM receptors and the activating receptor NKG2D.
Synonyms: SRF-231
Urabrelimab (SRF231) is a fully human monoclonal antibody targeting CD47. It effectively inhibits the interaction between CD47 and signal-regulatory protein alpha (SIRPĪ±), a critical pathway involved in evading phagocytosis by immune cells. This blockade can promote the engulfment and elimination of cancer cells, making it a valuable tool for oncology research.
Synonyms: CC-95251; BMS-986351
Anzurstobart (CC-95251; BMS-986351) is a fully human monoclonal antibody targeting SIRPĪ± with high affinity. This antibody effectively inhibits the interaction between CD47 and SIRPĪ±, a critical pathway that tumors exploit to evade immune destruction. By blocking this interaction, Anzurstobart enhances the phagocytic activity of macrophages, particularly in co-culture models of diffuse large B-cell lymphoma (DLBCL) when used in conjunction with Rituximab. This antibody is primarily researched for its therapeutic potential in both solid tumors and hematological malignancies, offering significant insights into immune checkpoint blockade strategies.
Synonyms: TJ011133; TJC4
Lemzoparlimab (TJ011133; TJC4) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody exhibits potent antitumor activity, making it a valuable tool for research in cancer immunotherapy. Lemzoparlimab functions by engaging with the CD47 protein, a key regulator in the 'don't eat me' signal that protects cancer cells from macrophage-mediated phagocytosis. By blocking this signal, Lemzoparlimab promotes the phagocytosis of malignant cells, thereby facilitating an immune response against the tumor. This mechanism highlights its potential utility in studies focused on tumor immunity and therapeutic antibody development.
Out of stock
All 3 sizes
Synonyms: IPH2201
Monalizumab (IPH2201) is a humanized monoclonal antibody designed to inhibit the immune checkpoint receptor Natural Killer Group 2A (NKG2A). By blocking NKG2A, Monalizumab enhances interferon-gamma (IFN-Ī³) production, which in turn augments the effector functions of natural killer (NK) cells. This antibody is primarily utilized in research focused on understanding and treating head and neck squamous cell carcinoma (HNSCC).
